Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Onyx Pharmaceuticals ( ONXX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.3%. By the end of trading, Onyx Pharmaceuticals rose $1.86 (2.3%) to $82.10 on average volume. Throughout the day, 1.5 million shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock ranged in a price between $79.93-$83.16 after having opened the day at $79.98 as compared to the previous trading day's close of $80.24. Other companies within the Drugs industry that increased today were: YM Biosciences ( YMI), up 76.7%, Idera Pharmaceuticals ( IDRA), up 35.3%, AspenBio Pharma ( APPY), up 30.1%, and ARCA biopharma ( ABIO), up 24.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $5.18 billion and is part of the health care sector. The company has a P/E ratio of 66.6, above the S&P 500 P/E ratio of 17.7. Shares are up 75.7% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall.

On the negative front, Acura Pharmaceuticals ( ACUR), down 15.2%, MEI Pharma ( MEIP), down 10.2%, Lifevantage Corporation ( LFVN), down 9.4%, and Opexa Therapeutics ( OPXA), down 9.3%, were all laggards within the drugs industry with Eli Lilly and Company ( LLY) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird

The Street Can't Help but Love Amgen

Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers

Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's "Water-Logged And Getting Wetter" Stock

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan